Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
💫Exciting news for bladder cancer patients💫:The EV-302 study met its dual primary endpoints of OS and OFS, compared to chemotherapy. An IDMC determined that OS crossed the pre-specified efficacy boundary at interim analysis. @BladderCancerUS@OncoAlert@DanaFarber_GU.
How can you tell Taylor Swift apart from the oncologist?
Well- Taylor Swift goes home from Chicago to a platinum record while the oncologist goes home with no platinum on record
Main speaker (7-8 pm EDT): Dr. Daniel Fein @DFein_MD from @BIDMC_Medicine on "Early drug development that might eventually be useful in prostate cancer"
https://t.co/7tqHg8H0Ep
This #PrideMonth, BILH celebrates all the patients, employees & allies that make up our vibrant #LGBTQ+ community. We collectively work to maintain safe, inclusive, welcoming environments that reduce barriers to the LGBTQ+ community's access to high-quality, equitable care.